Insights from 2023 ASH Annual Meeting


 

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Pts With Heavily Pretreated/Refractory CML and Ph+ ALL"

124 views
December 21, 2023
Comments 0
Login to view comments. Click here to Login